Results 21 to 30 of about 32,822 (166)

Personalized Antiplatelet Therapy Following Endovascular Revascularization in Peripheral Artery Occlusive Disease: A Novel Concept

EJVES Short Reports, 2015
: Case: A 73 year old patient with a longstanding history of peripheral artery occlusive disease (PAOD) presented with an acute on chronic progression of symptoms, based on a long occlusion of the superficial femoral artery (SFA), which was treated by ...
S.M.O. Peeters Weem, T.C. Leunissen, M. Teraa, E.J. Vonken, G.J. de Borst, F.L. Moll   +5 more
doaj   +1 more source

Dual Antiplatelet Therapy: A Concise Review for Clinicians

Life, 2023
Dual antiplatelet therapy (DAPT) combines two antiplatelet agents to decrease the risk of thrombotic complications associated with atherosclerotic cardiovascular diseases. Emerging data about the duration of DAPT is being published continuously. New approaches are trying to balance the time, benefits, and risks for patients taking DAPT for established ...
Hafeez Ul Hassan Virk, Johao Escobar, Mario Rodriguez, Eric R. Bates, Umair Khalid, Hani Jneid, Yochai Birnbaum, Glenn N. Levine, Sidney C. Smith, Chayakrit Krittanawong   +9 more
openaire   +4 more sources

Evaluation of race and ethnicity disparities in outcome studies of CYP2C19 genotype-guided antiplatelet therapy

Frontiers in Cardiovascular Medicine, 2022
Dual antiplatelet therapy with a P2Y12 inhibitor (clopidogrel, prasugrel, or ticagrelor) and aspirin remains the standard of care for all patients undergoing percutaneous coronary intervention (PCI).
Anh B. Nguyen, Larisa H. Cavallari, Joseph S. Rossi, George A. Stouffer, Craig R. Lee, Craig R. Lee   +5 more
doaj   +1 more source

Dual Antiplatelet Therapy De-escalation Strategies [PDF]

The American Journal of Cardiology, 2021
Dual antiplatelet therapy (DAPT), the combination of aspirin (ASA), and a P2Y12 inhibitor, protects against stent thrombosis and new atherothrombotic events after a stent implantation or an acute coronary syndrome, but exposes patients to an increased risk of bleeding.
Peter R, Sinnaeve, Tom, Adriaenssens
openaire   +2 more sources

Surgical tracheotomy performed with and without dual antiplatelet therapy

Open Medicine, 2014
Some patients who need dual antiplatelet therapy sometimes require tracheotomy. Aim of this study was to compare the rate of complications during and after surgical tracheotomy between patients requiring dual antiplatelet therapy and those without dual ...
Markota Andrej, Sinkovič Andreja, Čizmarević Bogdan   +2 more
doaj   +1 more source

The CLEAR (Considering Leading Experts’ Antithrombotic Regimes around peripheral angioplasty) survey: an international perspective on antiplatelet and anticoagulant practice for peripheral arterial endovascular intervention

CVIR Endovascular, 2019
Background Antiplatelet and anticoagulant therapy are commonly used before, during and after peripheral arterial endovascular intervention. This survey aimed to establish antiplatelet and anticoagulant choice for peripheral arterial endovascular ...
Kitty H. F. Wong, Dave C. Bosanquet, Graeme K. Ambler, Mahim I. Qureshi, Robert J. Hinchliffe, Christopher P. Twine, CLEAR survey collaborators   +6 more
doaj   +1 more source

Antithrombotic therapy after angioplasty of pulmonary vein stenosis due to atrial fibrillation ablation: A two‐center experience and review of the literature

Journal of Arrhythmia, 2022
Background Pulmonary vein stenosis (PVS) is a severe complication of atrial fibrillation (AF) ablation resulting in narrowing of affected pulmonary veins (PVs). Interventional treatment consists of angioplasty with or without PV stenting.
Thomas Fink, Julia Vogler, Riccardo Proietti, Vanessa Sciacca, Christian‐Hendrik Heeger, Laura Rottner, Tilman Maurer, Andreas Metzner, Shibu Mathew, Charlotte Eitel, Ingo Eitel, Christian Sohns, Makoto Sano, Bruno Reissmann, Andreas Rillig, Feifan Ouyang, Karl‐Heinz Kuck, Roland Richard Tilz   +17 more
doaj   +1 more source

Ultra-Early Combination Antiplatelet Therapy with Cilostazol for the Prevention of Branch Atheromatous Disease: A Multicenter Prospective Study

Cerebrovascular Diseases Extra, 2016
Background and Purpose: The optimal use of antiplatelet therapy for intracranial branch atheromatous disease (BAD) is not known. Methods: We conducted a prospective multicenter, single-group trial of 144 consecutive patients diagnosed with probable BAD ...
Teruo Kimura, Adam Tucker, Toshihide Sugimura, Toshitaka Seki, Shin Fukuda, Satoru Takeuchi, Shiro Miyata, Tsutomu Fujita, Akira Hashizume, Naoto Izumi, Kazutsune Kawasaki, Makoto Katsuno, Masaaki Hashimoto, Kazuhiro Sako   +13 more
doaj   +1 more source

Type and Duration of Dual Antiplatelet Therapy in Complex Percutaneous Coronary Intervention

US Cardiology Review, 2020
Complex percutaneous coronary intervention (PCI) patients are a high-risk population for ischemic complications. Antiplatelet therapy in such patients remains controversial, as the beneficial effects of more potent agents use or prolonged dual ...
Dimitrios Alexopoulos, Charalampos Varlamos, Despoina-Rafailia Benetou   +2 more
doaj   +1 more source

Bleeding complications related to external ventricular drainage placement in patients with ruptured intracranial aneurysms: a single-center study

Frontiers in Surgery
ObjectiveAcute aneurysmal rupture can be treated with endovascular therapy or surgical clipping. For patients with concurrent acute hydrocephalus, the placement of an external ventricular drainage (EVD) is required.
Yue Tang, Xiangping Zhong, Tingting Lin, Fujun Zuo, Min Fu, Li Wang, Xiaodu Yu, Dong Liu, Jincan Zhang   +8 more
doaj   +1 more source